Given that the most likely clinical scenario will involve patient treatment with ivosidenib until relapse, either as monotherapy or combined with chemotherapy, it is critical to consider the most appropriate strategy for targeting OXPHOS in ivosidenib-resistant IDH1-mutant AML cases. This evidence concerns the gene IDH1 and acute myeloid leukemia.